… Progress in both areas should advance preclinical assays of novel therapeutics. In that
regard, more progress in establishing patient-derived spheroid, organoid, and xenograft models …

… , overexpress this marker (65) and gastrinomas of the pancreas show low expression …
pancreatic marker. Nuclear positivity for PR has been reported in most pancreatic endocrine tumors…

… be used to study liver metastasis and to test novel therapeutic strategies (74,75). The limitations
… Lastly, improving detection of aggressive tumors by evaluating novel molecular markers …

… Expression of somatostatin receptor types 1-5 in 81 cases of gastrointestinal and
pancreatic endocrine tumors. A correlative immunohistochemical and reverse-transcriptase …

… Integration of high-grade components and molecular markers successfully led to
categorization of 19 out of 20 ambiguous cases [29]. This example highlights the vital need for the …

… to steer us toward the development of novel treatments. In this review, … proteins as potential
novel therapeutic targets in PDAC. … novel treatment strategies or novel targeted therapeutics. …

… incidence of this cancer. In this review, we summarize the state-of-the-art for the treatment
of metastatic PDAC, we explore novel therapies and outline future strategies in development. …

… With the progress in cancer profiling, treatment can now be customized for each individual.
The complexity of microRNA biology may also provide novel therapeutic options for the …

… Recent updates separate pancreatic neuroendocrine tumors into 2 broad … pancreatic
neuroendocrine tumors (panNET) and poorly differentiated pancreatic neuroendocrine carcinoma (…

… In this sense, the improvement in the biological knowledge of resistance mechanisms to
antiangiogenics would be relevant for novel therapies development that may improve patients’ …